A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels (TNT)

This study has been completed.

Sponsor:

Information provided by:

Pfizer

ClinicalTrials.gov Identifier:

NCT00327691

First received: May 16, 2006

Last updated: May 1, 2007

Last verified: May 2007

History of Changes

Purpose

The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.

Condition	Intervention	Phase
Cardiovascular Disease Cerebrovascular Accident Coronary Heart Disease	Drug: Atorvastatin	Phase 4

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention
Official Title:	The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD

Resource links provided by NLM:

MedlinePlus related topics: Cardiac Arrest Coronary Artery Disease Heart Diseases

Drug Information available for: Atorvastatin calcium

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

The primary outcome is the time to occurrence of a major
cardiovascular event, defined as the composite outcome of the
following clinical endpoints
CHD death
Non-fatal/Non-procedure related MI
Resuscitated cardiac arrest or fatal/non-fatal stroke

Secondary Outcome Measures:

The occurrence of the following clinical events
Major coronary event (CHD death, non fatal myocardial infarction or resuscitated cardiac arrest)
any coronary event (major coronary event or CABG
PTCA, other revascularization procedure, procedure-related myocardial infarction, or documented angina)
cerebrovascular event (fatal or non fatal stroke, TIA)
peripheral vascular disease; hospitalization with primary diagnosis' of CHF
any cardiovascular event (any of the above); and all-cause mortality.

Estimated Enrollment:	8600
Study Start Date:	April 1998
Estimated Study Completion Date:	August 2004

Eligibility

Ages Eligible for Study:	35 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men and women age 35-75 who have evident CHD

Exclusion Criteria:

Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00327691

Hide Study Locations

Locations

United States, Alabama
Pfizer Investigational Site
Alabaster, Alabama, United States, 35007
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-2041
Pfizer Investigational Site
Birmingham, Alabama, United States, 35213
Pfizer Investigational Site
Birmingham, Alabama, United States, 35205-4785
Pfizer Investigational Site
Hoover, Alabama, United States, 35216
Pfizer Investigational Site
Montgomery, Alabama, United States, 36117
United States, Arizona
Pfizer Investigational Site
Mesa, Arizona, United States, 85202
Pfizer Investigational Site
Mesa, Arizona, United States, 85206
United States, California
Pfizer Investigational Site
Burbank, California, United States, 91505
Pfizer Investigational Site
Camp Pendleton, California, United States, 92055
Pfizer Investigational Site
Fresno, California, United States, 93703
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
Loma Linda, California, United States, 92354
Pfizer Investigational Site
Los Angeles, California, United States, 90048
Pfizer Investigational Site
Los Angeles, California, United States, 90017-2395
Pfizer Investigational Site
Modesto, California, United States, 95350
Pfizer Investigational Site
Pasadena, California, United States, 91105
Pfizer Investigational Site
Rancho Mirage, California, United States, 92270
Pfizer Investigational Site
San Diego, California, United States, 92134-3303
Pfizer Investigational Site
San Francisco, California, United States, 94143-0326
Pfizer Investigational Site
San Francisco, California, United States, 94143-0130
Pfizer Investigational Site
Santa Rosa, California, United States, 95403
Pfizer Investigational Site
Stanford, California, United States
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States, 80012
Pfizer Investigational Site
Denver, Colorado, United States, 80220
Pfizer Investigational Site
Denver, Colorado, United States, 80203
Pfizer Investigational Site
Denver, Colorado, United States, 80218
United States, Connecticut
Pfizer Investigational Site
Bridgeport, Connecticut, United States, 06610
Pfizer Investigational Site
Hartford, Connecticut, United States, 06102
Pfizer Investigational Site
New Britain, Connecticut, United States, 06053
United States, Delaware
Pfizer Investigational Site
Newark, Delaware, United States, 19718
United States, District of Columbia
Pfizer Investigational Site
Washington, District of Columbia, United States, 20037
United States, Florida
Pfizer Investigational Site
Clearwater, Florida, United States, 33756
Pfizer Investigational Site
Gainsville, Florida, United States, 32610
Pfizer Investigational Site
Gainsville, Florida, United States, 32608
Pfizer Investigational Site
Hollywood, Florida, United States, 33021
Pfizer Investigational Site
Inverness, Florida, United States, 34452
Pfizer Investigational Site
Lakeland, Florida, United States, 33805
Pfizer Investigational Site
Miami, Florida, United States, 33176
Pfizer Investigational Site
Miami, Florida, United States, 33173
Pfizer Investigational Site
Ocala, Florida, United States, 34474
Pfizer Investigational Site
Orlando, Florida, United States, 32803
Pfizer Investigational Site
Port Charlotte, Florida, United States, 33952
Pfizer Investigational Site
Sarasota, Florida, United States, 34239
Pfizer Investigational Site
Stuart, Florida, United States, 34996
Pfizer Investigational Site
Tamarac, Florida, United States, 33321
Pfizer Investigational Site
The Villages, Florida, United States, 32159
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30309
Pfizer Investigational Site
Canton, Georgia, United States, 30114
United States, Illinois
Pfizer Investigational Site
Berwyn, Illinois, United States, 60402
Pfizer Investigational Site
Blue Island, Illinois, United States, 60406
Pfizer Investigational Site
Chicago, Illinois, United States, 60610
Pfizer Investigational Site
Chicago, Illinois, United States, 60611
Pfizer Investigational Site
DuQuoin, Illinois, United States, 62832
Pfizer Investigational Site
Evanston, Illinois, United States, 60201
Pfizer Investigational Site
Lake Forest, Illinois, United States, 60045
Pfizer Investigational Site
Marion, Illinois, United States, 62959
Pfizer Investigational Site
Pekin, Illinois, United States, 61554
Pfizer Investigational Site
Peoria, Illinois, United States, 61603
Pfizer Investigational Site
Peoria, Illinois, United States, 61614
United States, Indiana
Pfizer Investigational Site
Beech Grove, Indiana, United States, 46107
Pfizer Investigational Site
Evansville, Indiana, United States, 47710
Pfizer Investigational Site
Fort Wayne, Indiana, United States, 46805
Pfizer Investigational Site
Fort Wayne, Indiana, United States, 46825
Pfizer Investigational Site
Jeffersonville, Indiana, United States, 47130
Pfizer Investigational Site
Scottsburg, Indiana, United States, 47170
United States, Iowa
Pfizer Investigational Site
Des Moines, Iowa, United States, 50314
Pfizer Investigational Site
Iowa City, Iowa, United States, 52242
United States, Kansas
Pfizer Investigational Site
Kansas City, Kansas, United States, 66160-7200
Pfizer Investigational Site
Lathe, Kansas, United States, 66061
Pfizer Investigational Site
Overland Park, Kansas, United States, 66213
Pfizer Investigational Site
Wichita, Kansas, United States, 67220
United States, Kentucky
Pfizer Investigational Site
Edgewood, Kentucky, United States, 41017
Pfizer Investigational Site
Erlanger, Kentucky, United States, 41018
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202
United States, Louisiana
Pfizer Investigational Site
Marrero, Louisiana, United States, 70072
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70112
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70121
United States, Maine
Pfizer Investigational Site
Portland, Maine, United States, 04102
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21205
Pfizer Investigational Site
Baltimore, Maryland, United States, 21287
Pfizer Investigational Site
Baltimore, Maryland, United States, 21218
Pfizer Investigational Site
Baltimore, Maryland, United States, 21201
Pfizer Investigational Site
Baltimore, Maryland, United States, 21204
Pfizer Investigational Site
Baltimore, Maryland, United States, 21208
Pfizer Investigational Site
Baltimore, Maryland, United States, 21224
Pfizer Investigational Site
Baltimore, Maryland, United States, 21228
Pfizer Investigational Site
Baltimore, Maryland, United States, 21229
Pfizer Investigational Site
Baltimore, Maryland, United States, 21237
Pfizer Investigational Site
Bel Air, Maryland, United States, 21014
Pfizer Investigational Site
Westminster, Maryland, United States, 21157
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02111
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215
Pfizer Investigational Site
Burlington, Massachusetts, United States, 1805
United States, Michigan
Pfizer Investigational Site
Dearborn, Michigan, United States, 48126
Pfizer Investigational Site
Detroit, Michigan, United States, 48202
Pfizer Investigational Site
Farmington Hill, Michigan, United States, 48336
Pfizer Investigational Site
Sterling Heights, Michigan, United States, 48310
Pfizer Investigational Site
West Bloomfield, Michigan, United States, 48322
United States, Minnesota
Pfizer Investigational Site
Duluth, Minnesota, United States, 55805
Pfizer Investigational Site
Edina, Minnesota, United States, 55435
Pfizer Investigational Site
Maplewood, Minnesota, United States, 55109
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55455
Pfizer Investigational Site
St. Paul, Minnesota, United States, 55102
United States, Missouri
Pfizer Investigational Site
Kansas City, Missouri, United States, 64111
Pfizer Investigational Site
St. Louis, Missouri, United States, 63110-0205
Pfizer Investigational Site
St. Louis, Missouri, United States, 63117
Pfizer Investigational Site
St. Louis, Missouri, United States, 63110
Pfizer Investigational Site
St. Louis, Missouri, United States, 63104
Pfizer Investigational Site
St. Louis, Missouri, United States, 63141
United States, Nebraska
Pfizer Investigational Site
Papillion, Nebraska, United States, 68046
United States, New Hampshire
Pfizer Investigational Site
Manchester, New Hampshire, United States, 03102
United States, New Jersey
Pfizer Investigational Site
New Brunswick, New Jersey, United States, 08901
United States, New York
Pfizer Investigational Site
Albany, New York, United States, 12208
Pfizer Investigational Site
Brooklyn, New York, United States, 11203
Pfizer Investigational Site
Hawthorne, New York, United States, 10535
Pfizer Investigational Site
Manlius, New York, United States, 13104
Pfizer Investigational Site
New York, New York, United States, 10021
Pfizer Investigational Site
New York, New York, United States, 10032
Pfizer Investigational Site
New York, New York, United States, 10029
Pfizer Investigational Site
Rochester, New York, United States, 14607
Pfizer Investigational Site
Rochester, New York, United States, 14618
Pfizer Investigational Site
Rochester, New York, United States, 14621
Pfizer Investigational Site
Syracuse, New York, United States, 13202
Pfizer Investigational Site
Syracuse, New York, United States, 13210
Pfizer Investigational Site
Valhalla, New York, United States, 10595
United States, North Carolina
Pfizer Investigational Site
Asheville, North Carolina, United States, 28803
Pfizer Investigational Site
Durham, North Carolina, United States, 27710
Pfizer Investigational Site
Eden, North Carolina, United States, 27288
Pfizer Investigational Site
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Pfizer Investigational Site
Beachwood, Ohio, United States, 44122
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45246
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45219
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45229
Pfizer Investigational Site
Cleveland, Ohio, United States, 44106-5038
Pfizer Investigational Site
Cleveland, Ohio, United States, 44195
Pfizer Investigational Site
Columbus, Ohio, United States, 43210
Pfizer Investigational Site
Columbus, Ohio, United States, 43221
Pfizer Investigational Site
Kettering, Ohio, United States, 45429-1221
Pfizer Investigational Site
Lorain, Ohio, United States, 44053
Pfizer Investigational Site
Sandusky, Ohio, United States, 44870
United States, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73104
Pfizer Investigational Site
Tulsa, Oklahoma, United States, 74136
Pfizer Investigational Site
Tulsa, Oklahoma, United States, 74136-1920
Pfizer Investigational Site
Tulsa, Oklahoma, United States, 74133
United States, Oregon
Pfizer Investigational Site
Eugene, Oregon, United States, 97401
Pfizer Investigational Site
Portland, Oregon, United States, 97210
Pfizer Investigational Site
Portland, Oregon, United States, 97216
United States, Pennsylvania
Pfizer Investigational Site
Allentown, Pennsylvania, United States, 18102
Pfizer Investigational Site
Allentown, Pennsylvania, United States, 18106-0880
Pfizer Investigational Site
Lansdale, Pennsylvania, United States, 19446
Pfizer Investigational Site
Lehighton, Pennsylvania, United States, 18235
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19104
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19107
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Pfizer Investigational Site
Sellersville, Pennsylvania, United States, 18960
United States, Rhode Island
Pfizer Investigational Site
Pawtucket, Rhode Island, United States, 02860
Pfizer Investigational Site
Providence, Rhode Island, United States, 02906
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29403
United States, South Dakota
Pfizer Investigational Site
Sioux Falls, South Dakota, United States, 57105
Pfizer Investigational Site
Sioux Falls, South Dakota, United States, 57108
United States, Tennessee
Pfizer Investigational Site
Memphis, Tennessee, United States, 38105
Pfizer Investigational Site
Memphis, Tennessee, United States, 38119-5209
Pfizer Investigational Site
Memphis, Tennessee, United States, 38104
Pfizer Investigational Site
Memphis, Tennessee, United States, 38128
Pfizer Investigational Site
Nashville, Tennessee, United States, 37205
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232-6300
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78756
Pfizer Investigational Site
Dallas, Texas, United States, 75390-9047
Pfizer Investigational Site
Dallas, Texas, United States, 75235
Pfizer Investigational Site
Dallas, Texas, United States, 75246
Pfizer Investigational Site
Denton, Texas, United States, 76204
Pfizer Investigational Site
Houston, Texas, United States, 77030
Pfizer Investigational Site
Lackland AFB, Texas, United States, 78236-5300
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84124
United States, Vermont
Pfizer Investigational Site
Burlington, Vermont, United States, 05401
United States, Virginia
Pfizer Investigational Site
Richmond, Virginia, United States, 23298
Pfizer Investigational Site
Richmond, Virginia, United States, 23249
United States, Washington
Pfizer Investigational Site
Seattle, Washington, United States, 98104
United States, Wisconsin
Pfizer Investigational Site
Milwaukee, Wisconsin, United States, 53295
Australia, New South Wales
Pfizer Investigational Site
St. Leonards, New South Wales, Australia, 2065
Australia, Queensland
Pfizer Investigational Site
Auchenflower, Queensland, Australia, 4066
Pfizer Investigational Site
Brisbane, Queensland, Australia, 4029
Pfizer Investigational Site
Chermside, Queensland, Australia, 4032
Pfizer Investigational Site
Greenslopes, Queensland, Australia, 4130
Pfizer Investigational Site
Herston, Queensland, Australia, 4029
Pfizer Investigational Site
Milton, Queensland, Australia, 4064
Australia, South Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia, 5000
Pfizer Investigational Site
Bedford Park, South Australia, Australia, 5042
Australia, Tasmania
Pfizer Investigational Site
Hobart, Tasmania, Australia, 7000
Australia, Victoria
Pfizer Investigational Site
Clayton, Victoria, Australia, 3168
Pfizer Investigational Site
Parkville, Victoria, Australia, 3050
Pfizer Investigational Site
Prahran, Victoria, Australia, 3181
Australia, Western Australia
Pfizer Investigational Site
Nedlands, Western Australia, Australia, 6009
Austria
Pfizer Investigational Site
Feldkirch, Austria, A-6807
Pfizer Investigational Site
Oberpullendorf, Austria, A-7350
Pfizer Investigational Site
Wien, Austria, A-1090
Pfizer Investigational Site
Wien, Austria, 1100
Belgium
Pfizer Investigational Site
Aalst, Belgium, 9300
Pfizer Investigational Site
Antwerpen, Belgium, B-2020
Pfizer Investigational Site
Genk, Belgium, 3600
Pfizer Investigational Site
Genk, Belgium, B-3600
Pfizer Investigational Site
Godinne, Belgium, 5530
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Lommel, Belgium, 3920
Pfizer Investigational Site
Neerpelt, Belgium, 3910
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada, T2E 7C5
Pfizer Investigational Site
Calgary, Alberta, Canada, T2N 4N1
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 2B7
Pfizer Investigational Site
Edmonton, Alberta, Canada, T5R 4H5
Canada, British Columbia
Pfizer Investigational Site
Nanaimo, British Columbia, Canada, V9S 2B8
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V6R 1Y6
Pfizer Investigational Site
Victoria, British Columbia, Canada, V8T 5G4
Canada, Manitoba
Pfizer Investigational Site
Winnipeg, Manitoba, Canada, R3A 1R9
Canada, Newfoundland and Labrador
Pfizer Investigational Site
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Nova Scotia
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 3A7
Canada, Ontario
Pfizer Investigational Site
Hamilton, Ontario, Canada, L8L 2X2
Pfizer Investigational Site
London, Ontario, Canada, N6A 4G5
Pfizer Investigational Site
Ottawa, Ontario, Canada, K1Y 4W7
Pfizer Investigational Site
Sudbury, Ontario, Canada, P3E 1B8
Pfizer Investigational Site
Toronto, Ontario, Canada, M5C 2T2
Canada, Quebec
Pfizer Investigational Site
Chicoutimi, Quebec, Canada, G7H 5H6
Pfizer Investigational Site
Montreal, Quebec, Canada, H3A 1A1
Pfizer Investigational Site
Montreal, Quebec, Canada, H2W 1R7
Pfizer Investigational Site
Montreal, Quebec, Canada, H1T 1C8
Pfizer Investigational Site
Sherbrooke, Quebec, Canada, J1H 5N4
Pfizer Investigational Site
St-foy, Quebec, Canada, G1V 4G2
Canada
Pfizer Investigational Site
Quebec, Canada, G1R 2J6
France
Pfizer Investigational Site
Pessac, Cedex, France, 33604
Pfizer Investigational Site
Agen, France, 47000
Pfizer Investigational Site
Bordeaux, France, 33000
Pfizer Investigational Site
Brest, France, 29200
Pfizer Investigational Site
Clermont-ferrand, France, 63003
Pfizer Investigational Site
Lyon, France, 69003
Pfizer Investigational Site
Marseille, France, 13915 Cedex 20
Pfizer Investigational Site
Paris CEDEX 05, France, 75230
Pfizer Investigational Site
Rennes, France, 35033
Pfizer Investigational Site
Roubaix Cdx, France, 59056
Pfizer Investigational Site
Strasbourg, France, 67091
Pfizer Investigational Site
Toulouse, France, 31400
Pfizer Investigational Site
Toulouse, France, 31059
Germany
Pfizer Investigational Site
Berlin, Germany, 13439
Pfizer Investigational Site
Berlin, Germany, 13353
Pfizer Investigational Site
Essen, Germany, 45329
Pfizer Investigational Site
Hamburg, Germany, 20246
Pfizer Investigational Site
Schwerte, Germany, D-58239
Pfizer Investigational Site
Tostedt, Germany, 21255
Pfizer Investigational Site
Wurzburg, Germany, 97070
Ireland
Pfizer Investigational Site
Cork, Ireland
Pfizer Investigational Site
Dublin, Ireland, D8
Italy
Pfizer Investigational Site
Bologna, Italy, 40138
Pfizer Investigational Site
Bologna, Italy, 40139
Pfizer Investigational Site
Cuneo, Italy, 12100
Pfizer Investigational Site
Firenze, Italy, 50134
Pfizer Investigational Site
Napoli, Italy, 80131
Pfizer Investigational Site
Rome, Italy, 00184
Pfizer Investigational Site
Udine, Italy, 33100
Netherlands
Pfizer Investigational Site
's-Hertogenbosch, Netherlands, 5211 NL
Pfizer Investigational Site
Alkmaar, Netherlands, 1815 JD
Pfizer Investigational Site
Amersfoort, Netherlands, 3818 ES
Pfizer Investigational Site
Amsterdam, Netherlands, 1105 AZ
Pfizer Investigational Site
Breda, Netherlands, 4818 CK
Pfizer Investigational Site
Eindhoven, Netherlands, 5623 EJ
Pfizer Investigational Site
Enschede, Netherlands, 7513 ER
Pfizer Investigational Site
Groningen, Netherlands, 9728 NZ
Pfizer Investigational Site
Groningen, Netherlands, 9713 GZ
Pfizer Investigational Site
Leiden, Netherlands, 2333 ZA
Pfizer Investigational Site
Nieuwegein, Netherlands, 3435 CM
Pfizer Investigational Site
Nijmegen, Netherlands, 6532 SZ
Pfizer Investigational Site
Zwolle, Netherlands, 8025 AB
Pfizer Investigational Site
Zwolle, Netherlands, 8011 JW
South Africa
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa, 2193
Pfizer Investigational Site
Sunninghill, Gauteng, South Africa, 2157
Pfizer Investigational Site
Bloemfontein, South Africa, 9301
Pfizer Investigational Site
Cape Town, South Africa, 7405
Pfizer Investigational Site
Cape Town, South Africa, 7500
Pfizer Investigational Site
Parow, South Africa, 7505
Spain
Pfizer Investigational Site
Unknown, Madrid, Spain, 28040
Pfizer Investigational Site
Barcelona, Spain, 08035
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Cordoba, Spain, 14004
Pfizer Investigational Site
Madrid, Spain, 28029
Pfizer Investigational Site
Madrid, Spain, 28041
Pfizer Investigational Site
Madrid, Spain, 28007
Pfizer Investigational Site
Madrid, Spain, 28040
Pfizer Investigational Site
San Sebastian, Spain, 20014
Pfizer Investigational Site
Santiago de Compostela, Spain, 15706
Pfizer Investigational Site
Sevilla, Spain, 41013
Pfizer Investigational Site
Sevilla, Spain, 41009
Pfizer Investigational Site
Valladolid, Spain, 47011
Pfizer Investigational Site
Zaragoza, Spain, 50009
Switzerland
Pfizer Investigational Site
Bern, Switzerland, 3010
Pfizer Investigational Site
Geneve 14, Switzerland, CH-1211
Pfizer Investigational Site
Lausanne, Switzerland, CH-1011
Pfizer Investigational Site
Lugano, Switzerland, 6900
Pfizer Investigational Site
St Gallen, Switzerland, CH-9007
United Kingdom
Pfizer Investigational Site
Romford, Essex, United Kingdom, RM7 OBE
Pfizer Investigational Site
London, Greater London, United Kingdom, NW10 7NS
Pfizer Investigational Site
London, Greater London, United Kingdom, SW17 0RE
Pfizer Investigational Site
London, Greater London, United Kingdom, E2 9JX
Pfizer Investigational Site
Aldershot, Hampshire, United Kingdom, GU11 3RB
Pfizer Investigational Site
Farnborough, Kent, United Kingdom, BR6 7AR
Pfizer Investigational Site
Blackpool, Lancashire, United Kingdom, FY3 8NR
Pfizer Investigational Site
Leicester, Leicestershire, United Kingdom, LE3 9QP
Pfizer Investigational Site
London, Middlesex, United Kingdom, HA8 0AD
Pfizer Investigational Site
Coventry, West Midlands, United Kingdom, CV1 4FH
Pfizer Investigational Site
Coventry, West Midlands, United Kingdom, CV2 2DX
Pfizer Investigational Site
Swindon, Wiltshire, United Kingdom, SN3 6BB
Pfizer Investigational Site
Barnet, United Kingdom, EN5 3DJ
Pfizer Investigational Site
Glasgow, United Kingdom, G11 6NT
Pfizer Investigational Site
London, United Kingdom, E1 1BB
Pfizer Investigational Site
London, United Kingdom, NW3 2PF
Pfizer Investigational Site
Paisley, United Kingdom, P1 1HR

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

Publications:

Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. Epub 2006 Oct 17.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524. PubMed PMID: 22576673.

Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F, Petrides F, Rye KA, DeMicco DA, Barter PJ, Kastelein JJ, Lambert G. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012 May 15;59(20):1778-84.

Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24;125(16):1979-87. Epub 2012 Mar 29.

Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, DeMicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, LaRosa JC, Pedersen TR, Kastelein JJ; TNT and IDEAL Investigators. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet. 2012 Feb 1;5(1):51-7. Epub 2011 Dec 1.

Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2010 Dec 28;57(1):63-9.

Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. Epub 2010 Feb 3.

Waters DD. Clinical insights from the treating to new targets trial. Prog Cardiovasc Dis. 2009 May-Jun;51(6):487-502.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54.

Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10.

ClinicalTrials.gov Identifier:	NCT00327691 History of Changes
Other Study ID Numbers:	0981-117, A2581136
Study First Received:	May 16, 2006
Last Updated:	May 1, 2007
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

Major cardiovascular event
Major Coronary event
Revascularization

Additional relevant MeSH terms:

Cardiovascular Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cerebral Infarction
Stroke
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders

Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Atorvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2013

To Top